Why Is Immix Biopharma (IMMX) Stock Down -13.17% Today?
Key Takeaways
- Immix Biopharma shares plunged 13.17% during trading on July 20, 2026, following a bombshell report that the company's recently hired chief medical officer was a fugitive living under a false identity.
- The CMO hired as "Richard Graydon" was actually Ronald Fischer, a 70-year-old former anesthesiologist who disappeared in 2005 while on trial for first-degree sexual assault and had been on Rhode Island's most-wanted list for over two decades.
- Multiple law firms have launched investigations into potential securities fraud, including Block & Leviton and Kehoe Law Firm, examining whether Immix or its executives violated federal securities laws.
- Trading volume surged well above average, reflecting panic selling and elevated investor anxiety as the scandal reverberated through the market.
- Broader biotech sector sentiment remained mixed, but IMMX's decline was company-specific and driven entirely by the governance crisis rather than sector-wide headwinds.
- Investors now watch for further regulatory disclosures, potential shareholder litigation, and how the company addresses the reputational and legal fallout in the days ahead.
Opening Summary
IMMX, the ticker for Immix Biopharma, Inc. — a clinical-stage biopharmaceutical company developing CAR-T cell therapies for AL Amyloidosis and other serious diseases — saw its shares crater 13.17% on Monday, July 20, 2026. The stock dropped from a previous close of $10.25 on July 17 to $8.90, as investors recoiled from an extraordinary revelation: the company's chief medical officer, hired in March under the name Richard Graydon, was unmasked as Ronald Fischer, a convicted sex offender and one of Rhode Island's most-wanted fugitives who had been on the run for 20 years. The scandal, first reported by STAT News, has triggered securities fraud investigations by multiple law firms and cast a harsh spotlight on Immix Biopharma's executive vetting and governance practices.
CMO Fugitive Scandal Rocks Investor Confidence
The primary catalyst behind IMMX's sharp decline was a STAT News investigation published Sunday that connected the dots between Immix Biopharma's recently terminated chief medical officer and one of Rhode Island's longest-running fugitive cases. Ronald Fischer, 70, a former anesthesiologist, vanished in 2005 while standing trial for first-degree sexual assault and was subsequently convicted in absentia. He remained at large for two decades — until federal and Rhode Island authorities tracked and boarded a 56-foot sailboat off the coast of New Jersey last week, where he was arrested. The boat was registered under the alias Richard Graydon.
That alias, as STAT uncovered, was the same name under which Fischer had secured a position as chief medical officer at Immix Biopharma in March 2026. The company had publicly touted "Graydon" as a board-certified hematologist-oncologist with over 20 years of clinical development experience, claiming he had previously worked at Merck and Johnson & Johnson on blockbuster cancer drugs including Keytruda, Darzalex, Carvykti, and Imbruvica. The press release announcing his March 30 hiring has since been scrubbed from the company's website.
Immix disclosed in a July 17 SEC filing that Graydon had been terminated "for reasons unrelated to his activities at the Company." Management characterized his tenure as brief and stated there would be no material impact on the business. However, investors clearly disagreed, punishing the stock as the reputational damage and governance concerns mounted.
Securities Fraud Investigations Add Legal Overhang
Compounding the selloff, at least two prominent plaintiff-side law firms — Block & Leviton and Kehoe Law Firm — announced they have opened investigations into whether Immix Biopharma or its executives violated federal securities laws. These investigations center on whether the company made materially false or misleading statements about its leadership, particularly in connection with the background and qualifications of its former chief medical officer.
"This is an extraordinary situation where a company's senior executive appears to have been operating under a false identity for years," said Michael Yarnoff, a partner at Kehoe Law Firm, which is probing potential securities claims. "Investors who purchased Immix stock based on the company's representations about its leadership may have grounds for recovery." The threat of shareholder litigation and potential regulatory scrutiny adds a layer of uncertainty that is particularly damaging for a clinical-stage biotech company with no commercial revenue, where investor trust in management is paramount.
Market Context and Trading Activity
The selloff in IMMX was accompanied by a dramatic surge in trading volume. With more than 2.8 million shares changing hands during Monday's session, volume roughly doubled the stock's recent daily average of approximately 1.2 million shares, signaling intense liquidation pressure. The stock opened near $10.00 and steadily declined throughout the session, touching an intraday low of $8.67 before settling near $8.90.
The decline was entirely company-specific. Broader biotech sector benchmarks and major indices did not exhibit comparable weakness, underscoring that the IMMX selloff was driven by the fugitive-executive scandal and its legal ramifications rather than any macroeconomic or sector-wide headwind. The stock had already been under pressure in the preceding sessions, having declined from its 52-week high of $12.14 reached on July 7, but Monday's plunge represented the steepest single-day drop since March 2026.
The scandal also raises uncomfortable questions about the due diligence processes at Immix — and potentially at Atossa Therapeutics, another Seattle-based biotech that had previously hired "Graydon" as interim chief medical officer in October 2022. For a clinical-stage company that relies heavily on the credibility of its clinical and regulatory strategy to attract capital and advance its pipeline, the governance failure represents a significant setback.
Trending AI Robots
In periods of heightened volatility and uncertainty — such as the governance-driven selloff currently impacting IMMX — traders and investors often turn to algorithm-driven tools to help navigate fast-moving markets. Tickeron's Trending AI Robots page features a curated selection of AI-powered trading bots that are currently demonstrating the strongest performance under prevailing market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only those that have proven most effective in real-time environments are highlighted in this section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to identify approaches aligned with their own risk tolerance and objectives. Explore the Trending AI Robots page to discover which automated strategies are currently outperforming.
What Comes Next for IMMX
The immediate priority for Immix Biopharma will be managing the legal and reputational fallout from the CMO scandal. With Block & Leviton and Kehoe Law Firm already circling, the company may face formal shareholder complaints or securities class-action litigation in the coming weeks. How aggressively the SEC or other regulators choose to scrutinize the matter remains an open question, but any additional inquiry would amplify the overhang on the stock.
Operationally, Immix must reassure investors that its core clinical programs — particularly the NEXICART-2 registrational study of NXC-201 in relapsed/refractory AL Amyloidosis — remain on track. The company recently met the primary endpoint at interim results presented at ASCO 2025, and NXC-201 holds Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA as well as Orphan Drug Designation in both the U.S. and EU. Upcoming clinical updates and potential data presentations at major medical conferences will be critical in refocusing market attention on the pipeline rather than the scandal.
On the financial front, Immix raised $100 million in an upsized underwritten offering in December 2025, providing a cash runway into mid-2027. This capital cushion may help the company weather the near-term turbulence, though the cost of capital and investor appetite for any future financings could be affected by the governance concerns. Analysts had maintained a consensus "Moderate Buy" rating on the stock prior to the scandal, but the events of July 20 may prompt a reassessment of risk premiums and governance discount applied to the shares. The company's next earnings report, expected in early August 2026, will be closely watched for management's commentary on the situation.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
IMMX in downward trend: price dove below 50-day moving average on September 25, 2026
IMMX moved below its 50-day moving average on September 25, 2026 date and that indicates a change from an upward trend to a downward trend. In 32 of 34 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 08, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IMMX as a result. In 77 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.
The Moving Average Convergence Divergence Histogram (MACD) for IMMX turned negative on September 04, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 44 similar instances when the indicator turned negative. In 36 of the 44 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
The 10-day moving average for IMMX crossed bearishly below the 50-day moving average on October 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMMX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for IMMX entered a downward trend on October 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMMX's RSI Oscillator exited the oversold zone, 23 of 28 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
IMMX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.584) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. IMMX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMMX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement